What SPRAVATO is
SPRAVATO is a prescription esketamine nasal spray with FDA-labeled uses for certain adults with depression. It is not dispensed for unsupervised home use.
A qualified prescriber must determine whether the diagnosis, prior treatment, current medications, blood pressure, substance-use risk, pregnancy considerations, and safety profile fit the labeled treatment pathway.
Why treatment is supervised
The FDA labeling and REMS program require administration in a certified healthcare setting because patients need observation for important risks after dosing.
The current prescribing information describes risks including sedation, dissociation, respiratory depression, blood-pressure increases, and abuse or misuse. Patients are monitored for at least two hours after administration, need transportation home, and should not drive or operate machinery until the next day after a restful sleep.
What to ask a treatment center
Confirm REMS certification, psychiatric oversight, monitoring, transportation rules, insurance requirements, and how the center coordinates the rest of your depression care.
- Who confirms the diagnosis and decides whether SPRAVATO fits?
- Is this location certified under the SPRAVATO REMS?
- What happens during the monitoring period, and who responds if symptoms worsen?
- How are other medications, psychotherapy, and follow-up coordinated?
- What does insurance require, and what out-of-pocket costs should I expect?
A critical safety distinction
SPRAVATO has not been shown to prevent suicide or replace hospitalization when hospitalization is clinically warranted.
Urgent suicidal thoughts, an immediate plan, or danger to self or others require crisis or emergency care. A scheduled outpatient treatment visit is not a substitute for that response.
Common questions
Questions patients and families ask
Is SPRAVATO the same as ketamine?
No. SPRAVATO contains esketamine and follows an FDA-approved, REMS-controlled pathway. Ketamine products have different approval, formulation, evidence, and monitoring considerations.
Can I take SPRAVATO at home?
No. It is administered under supervision in a certified healthcare setting, followed by monitoring.
Does SPRAVATO guarantee rapid relief?
No. Response varies, and the FDA label includes specific limitations. A center should explain realistic goals, risks, monitoring, and what happens if improvement is limited.
Primary sources
Review the evidence directly
Source links support education, not a personal treatment recommendation. Exact candidacy and risk must be assessed by a qualified clinician.